NKTR looks de-risked after positive Rezpeg phase 2 data in atopic dermatitis & alopecia areata, with 80% upside and $1.1B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results